• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Valneva Se ADR (NQ: VALN )

    7.760 +0.110 (+1.44%)
    Streaming Delayed Price Updated: 11:05 AM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,661
    Open 7.760
    Bid (Size) 7.650 (2)
    Ask (Size) 7.900 (3)
    Prev. Close 7.650
    Today's Range 7.630 - 7.760
    52wk Range 6.390 - 14.49
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
    Via Benzinga

    Performance

    YTD
    -24.22%
    -24.22%
    1 Month
    +8.26%
    +8.26%
    3 Month
    -8.92%
    -8.92%
    6 Month
    +7.78%
    +7.78%
    1 Year
    -44.57%
    -44.57%

    More News

    Read More
    Analyst Scoreboard: 8 Ratings For Valneva
    Via Benzinga
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    The Analyst Landscape: 6 Takes On Valneva
    Via Benzinga
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Valneva
    Via Benzinga
    VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    3 Promising Biotech Stocks You Can Pick Up for Less Than $10
    Via InvestorPlace
    Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
    Via Benzinga
    Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
    Via Benzinga
    VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
    Via InvestorPlace
    Expert Ratings for Valneva
    Via Benzinga
    Analyst Ratings for Valneva
    Via Benzinga
    National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Novavax’s dispute resolution and upcoming earnings call
    Via MarketBeat
    Topics Earnings
    Exposures COVID-19 Financial
    Analyst Ratings for Valneva
    Via Benzinga
    Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
    Via Benzinga
    Exposures Product Safety
    McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
    Via Benzinga
    Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
    Via Benzinga
    FDA Approves World's First Mosquito-Borne Chikungunya Vaccine
    Via Benzinga
    Exposures Product Safety
    Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.